JP2016501878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501878A5 JP2016501878A5 JP2015545601A JP2015545601A JP2016501878A5 JP 2016501878 A5 JP2016501878 A5 JP 2016501878A5 JP 2015545601 A JP2015545601 A JP 2015545601A JP 2015545601 A JP2015545601 A JP 2015545601A JP 2016501878 A5 JP2016501878 A5 JP 2016501878A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrinogen
- group
- solution
- vwf
- factor viii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 14
- 108010049003 Fibrinogen Proteins 0.000 claims 12
- 102000008946 Fibrinogen Human genes 0.000 claims 12
- 229940012952 fibrinogen Drugs 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 108010047303 von Willebrand Factor Proteins 0.000 claims 10
- 102100036537 von Willebrand factor Human genes 0.000 claims 10
- 229960001134 von willebrand factor Drugs 0.000 claims 10
- 108010054218 Factor VIII Proteins 0.000 claims 9
- 102000001690 Factor VIII Human genes 0.000 claims 9
- 229960000301 factor viii Drugs 0.000 claims 9
- 239000012539 chromatography resin Substances 0.000 claims 8
- 239000002994 raw material Substances 0.000 claims 8
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- 230000006698 induction Effects 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 102000035195 Peptidases Human genes 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 3
- 102000013566 Plasminogen Human genes 0.000 claims 3
- 108010051456 Plasminogen Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 3
- 208000002004 Afibrinogenemia Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 238000005571 anion exchange chromatography Methods 0.000 claims 2
- 230000002779 inactivation Effects 0.000 claims 2
- 239000011347 resin Substances 0.000 claims 2
- 229920005989 resin Polymers 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims 1
- DAPOMFMFTBUAKL-UHFFFAOYSA-N 2-ethylpyridine-3-thiol Chemical compound CCC1=NC=CC=C1S DAPOMFMFTBUAKL-UHFFFAOYSA-N 0.000 claims 1
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 claims 1
- 206010016075 Factor I deficiency Diseases 0.000 claims 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims 1
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000003957 anion exchange resin Substances 0.000 claims 1
- 201000007182 congenital afibrinogenemia Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012149 elution buffer Substances 0.000 claims 1
- 238000011067 equilibration Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261733761P | 2012-12-05 | 2012-12-05 | |
| US61/733,761 | 2012-12-05 | ||
| EP13153898.5 | 2013-02-04 | ||
| EP13153898 | 2013-02-04 | ||
| US13/803,740 US20140154233A1 (en) | 2012-12-05 | 2013-03-14 | Method of purifying therapeutic proteins |
| US13/803,740 | 2013-03-14 | ||
| AU2013203357A AU2013203357B2 (en) | 2012-12-05 | 2013-04-10 | A method of purifying therapeutic proteins |
| AU2013203357 | 2013-04-10 | ||
| PCT/AU2013/001414 WO2014085861A1 (en) | 2012-12-05 | 2013-12-05 | A method of purifying therapeutic proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018178301A Division JP6836562B2 (ja) | 2012-12-05 | 2018-09-25 | 治療タンパク質の精製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501878A JP2016501878A (ja) | 2016-01-21 |
| JP2016501878A5 true JP2016501878A5 (https=) | 2017-01-19 |
| JP6411360B2 JP6411360B2 (ja) | 2018-10-24 |
Family
ID=47630209
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545601A Active JP6411360B2 (ja) | 2012-12-05 | 2013-12-05 | 治療タンパク質の精製方法 |
| JP2018178301A Active JP6836562B2 (ja) | 2012-12-05 | 2018-09-25 | 治療タンパク質の精製方法 |
| JP2021016182A Active JP7774384B2 (ja) | 2012-12-05 | 2021-02-04 | 治療タンパク質の精製方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018178301A Active JP6836562B2 (ja) | 2012-12-05 | 2018-09-25 | 治療タンパク質の精製方法 |
| JP2021016182A Active JP7774384B2 (ja) | 2012-12-05 | 2021-02-04 | 治療タンパク質の精製方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20140154233A1 (https=) |
| EP (2) | EP3483173A1 (https=) |
| JP (3) | JP6411360B2 (https=) |
| KR (2) | KR102240978B1 (https=) |
| CN (2) | CN109125714B (https=) |
| AU (2) | AU2013203357B2 (https=) |
| BR (1) | BR112015012854B1 (https=) |
| CA (2) | CA2893373A1 (https=) |
| PL (1) | PL2928905T3 (https=) |
| RU (1) | RU2685956C2 (https=) |
| SG (2) | SG10201704484QA (https=) |
| WO (1) | WO2014085861A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX351340B (es) | 2012-03-13 | 2017-10-11 | Octapharma Ag | Proceso mejorado para la produccion de fibrinogeno y fibrinogeno producido por este. |
| US10188965B2 (en) | 2012-12-05 | 2019-01-29 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic depletion of a protein from a solution |
| US20140154233A1 (en) | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
| GB201506113D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| GB201506117D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| AU2017205364B2 (en) * | 2016-01-07 | 2021-03-04 | Eio Biomedical Ltd | Methods, compositions and kits for reducing tissue adhesions |
| EP4293116A3 (fr) | 2016-07-06 | 2024-01-24 | Laboratoire Français du Fractionnement et des Biotechnologies | Fibrinogène liquide stable |
| CA3035650A1 (en) * | 2016-09-01 | 2018-03-08 | Plas-Free Ltd | Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders |
| KR20200038309A (ko) * | 2017-08-23 | 2020-04-10 | 체에스엘 베링 게엠베하 | 폰 빌레브란트 인자의 바이러스 여과 방법 |
| ES2983341T3 (es) * | 2018-02-28 | 2024-10-22 | Plas Free Ltd | Dispositivo extracorpóreo y matriz para la eliminación de proteínas fibrinolíticas de fluidos biológicos, métodos y usos de los mismos |
| CN109078628B (zh) * | 2018-08-27 | 2021-06-11 | 西北大学 | 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用 |
| FR3090321B1 (fr) * | 2018-12-21 | 2023-07-14 | Lab Francais Du Fractionnement | Procédé de filtration du fibrinogène |
| US12173307B2 (en) * | 2020-06-24 | 2024-12-24 | Bioverativ Therapeutics Inc. | Methods for the purification of viral vectors |
| CN116322920A (zh) | 2020-11-09 | 2023-06-23 | 武田药品工业株式会社 | 使用氧化硅吸附从血浆中纯化fviii |
| WO2022218962A1 (en) | 2021-04-13 | 2022-10-20 | Grifols Worldwide Operations Limited | Liquid composition comprising factor viii or factor viii/von willebrand factor complex |
| CN115181178B (zh) * | 2021-09-04 | 2024-04-26 | 广东双林生物制药有限公司 | 一种从冷沉淀中制备人纤维蛋白原的方法 |
| EP4456935A1 (en) | 2021-12-30 | 2024-11-06 | Baxter International Inc. | Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4764369A (en) | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| FR2632309B1 (fr) * | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
| ATE180492T1 (de) * | 1991-09-05 | 1999-06-15 | Baxter Int | Topischer fibrinogenkomplex |
| FR2686883B1 (fr) * | 1992-02-04 | 1994-05-13 | Aquitaine Develop Transf Sanguin | Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant. |
| ES2139227T5 (es) | 1994-07-14 | 2011-05-04 | Caf-Dcf Département Central De Fractionnement De La Croix Rouge S.C.R.L. | Concentrado de fibrinógeno obtenido de plasma sanguíneo, procedimiento e instalación para su preparación. |
| CA2198928A1 (en) * | 1994-09-02 | 1996-03-14 | Samar Nath Roy | Production and secretion of recombinant fibrinogen by yeast |
| US6037457A (en) * | 1997-01-31 | 2000-03-14 | The University Of North Carolina At Chapel Hill | Method for recombinant fibrinogen production |
| FR2772381B1 (fr) | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
| ATE328007T1 (de) * | 1998-09-24 | 2006-06-15 | Pharming Intellectual Pty Bv | Reinigung von fibrinogen aus flüssigkeiten mittels ausfällung und hydrophobischer- interaktion-chromatographie |
| WO2001048016A1 (en) | 1999-12-23 | 2001-07-05 | Csl Limited | Separation of fibrinogen from plasma proteases |
| WO2001046016A1 (en) | 1999-12-23 | 2001-06-28 | Rast Rodger H | System and method for providing individualized dosing |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| SK288005B6 (sk) * | 2001-05-21 | 2012-10-02 | Omrix Biopharmaceuticals S. A. | In vitro method for specifically removing or isolating plasminogen or plasmin and support used in this method |
| AUPR638801A0 (en) | 2001-07-13 | 2001-08-09 | Life Therapeutics Limited | Factor viii separation |
| WO2003028743A1 (en) * | 2001-10-03 | 2003-04-10 | Woolverton Christopher J | Storage-stable fibrinogen solutions |
| AU2002340776A1 (en) * | 2001-10-30 | 2003-05-12 | Novozymes A/S | High throughput isolation of proteins by charge induction chromatography |
| DE10211632A1 (de) | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration |
| CA2478925C (en) | 2002-04-26 | 2016-06-07 | Robert Lee Fahrner | Non-affinity purification of proteins |
| GB0216001D0 (en) * | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| DE10261126A1 (de) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
| DE10246125A1 (de) | 2002-10-01 | 2004-04-15 | Aventis Behring Gmbh | Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren |
| ES2214967B1 (es) | 2003-03-06 | 2005-06-16 | Probitas Pharma, S.A | Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento. |
| DE102004009400A1 (de) * | 2004-02-24 | 2005-09-08 | Zlb Behring Gmbh | Fibrinogen Reinigung |
| CA2583081A1 (en) * | 2004-06-16 | 2006-01-19 | Bio-Rad Laboratories, Inc. | Multichemistry fractionation |
| DK2102335T3 (da) * | 2007-01-04 | 2012-05-07 | Crucell Holland Bv | Rensning af faktor XI |
| US8399620B2 (en) | 2007-07-11 | 2013-03-19 | Novo Nordisk A/S | Purification of factor VIII using a mixed-mode or multimodal resin |
| EP2027875A1 (en) | 2007-08-23 | 2009-02-25 | Octapharma AG | A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC) |
| FR2920429B1 (fr) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | Procede de purification du facteur viii et du facteur von willebrand |
| WO2009090056A2 (en) | 2008-01-18 | 2009-07-23 | F. Hoffmann-La Roche Ag | Purification of not-glycosylated polypeptides |
| KR20160104740A (ko) * | 2008-06-24 | 2016-09-05 | 옥타파마 아게 | 응고 인자 ｖｉｉｉ을 정제하는 방법 |
| DK2521566T3 (en) * | 2010-01-08 | 2014-12-08 | Profibrix Bv | Fibrinogen preparations enriched with fibrinogen with an extended alpha chain |
| WO2012038410A1 (en) | 2010-09-20 | 2012-03-29 | Octapharma Ag | Process for production of fibrinogen |
| CN103429609A (zh) * | 2010-12-08 | 2013-12-04 | 安姆根有限公司 | 在氨基酸存在下的离子交换层析 |
| MX351340B (es) | 2012-03-13 | 2017-10-11 | Octapharma Ag | Proceso mejorado para la produccion de fibrinogeno y fibrinogeno producido por este. |
| US20140154233A1 (en) | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
-
2013
- 2013-03-14 US US13/803,740 patent/US20140154233A1/en not_active Abandoned
- 2013-04-10 AU AU2013203357A patent/AU2013203357B2/en active Active
- 2013-12-05 KR KR1020157017824A patent/KR102240978B1/ko active Active
- 2013-12-05 PL PL13861334T patent/PL2928905T3/pl unknown
- 2013-12-05 RU RU2015126551A patent/RU2685956C2/ru active
- 2013-12-05 AU AU2013354899A patent/AU2013354899B2/en active Active
- 2013-12-05 WO PCT/AU2013/001414 patent/WO2014085861A1/en not_active Ceased
- 2013-12-05 BR BR112015012854-8A patent/BR112015012854B1/pt active IP Right Grant
- 2013-12-05 SG SG10201704484QA patent/SG10201704484QA/en unknown
- 2013-12-05 CA CA2893373A patent/CA2893373A1/en not_active Abandoned
- 2013-12-05 CN CN201811091750.9A patent/CN109125714B/zh active Active
- 2013-12-05 KR KR1020217010484A patent/KR102403847B1/ko active Active
- 2013-12-05 CA CA3185085A patent/CA3185085A1/en active Pending
- 2013-12-05 CN CN201380063945.1A patent/CN104981476B/zh active Active
- 2013-12-05 EP EP18207150.6A patent/EP3483173A1/en active Pending
- 2013-12-05 SG SG11201504372UA patent/SG11201504372UA/en unknown
- 2013-12-05 EP EP13861334.4A patent/EP2928905B1/en active Active
- 2013-12-05 JP JP2015545601A patent/JP6411360B2/ja active Active
-
2014
- 2014-11-06 US US14/535,085 patent/US9598461B2/en active Active
-
2017
- 2017-02-03 US US15/424,072 patent/US20170143805A1/en not_active Abandoned
-
2018
- 2018-09-25 JP JP2018178301A patent/JP6836562B2/ja active Active
- 2018-12-10 US US16/214,519 patent/US11426680B2/en active Active
-
2021
- 2021-02-04 JP JP2021016182A patent/JP7774384B2/ja active Active
- 2021-03-01 US US17/188,173 patent/US20210283530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501878A5 (https=) | ||
| Franchini et al. | The history of hemophilia | |
| RU2015126551A (ru) | Способ очистки лечебных белков | |
| Berntorp et al. | Modern haemophilia care | |
| Walsh et al. | The burden of inhibitors in haemophilia patients | |
| HRP20201973T1 (hr) | Ligandi modificirani kružnom permutacijom kao agonisti i antagonisti | |
| Teoh et al. | p53 abnormalities and potential therapeutic targeting in multiple myeloma | |
| EP4548972A3 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| JP2013514073A5 (https=) | ||
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2018521135A5 (https=) | ||
| JP2012532136A5 (https=) | ||
| MY178445A (en) | Novel antibody binding to tfpi and composition comprising the same | |
| PE20141473A1 (es) | Senalizacion slit-robo para el diagnostico y tratamiento de la enfermedad renal | |
| CN102580062A (zh) | 人凝血因子Ⅷ与vWF复合物或人凝血因子Ⅷ制剂的干热处理稳定剂 | |
| CN102584983A (zh) | 一种分离纯化凝血因子viii的方法 | |
| Ettingshausen et al. | The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? | |
| JP2015514115A5 (https=) | ||
| RU2015121574A (ru) | Препарат для биспецифических активаторов т-клеток(bite) | |
| K. Lau et al. | Thrombotic complications of neonates and children with congenital nephrotic syndrome | |
| CN102441172A (zh) | 高纯度凝血酶原复合物制品冷冻干燥稳定剂 | |
| Di Minno et al. | Management of patients with long‐term inhibitors: is immune tolerance an underestimated life‐long solution? | |
| RU2014123166A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| Goubran et al. | New monoclonal/bi-specific antibodies: reshaping transfusion medicine beyond replacement | |
| JP2008517046A5 (https=) |